ArticleProstate cancer and prostatic diseases2013
Prostate cancer disease severity and country of origin among black men in the United States.
Article in Prostate cancer and prostatic diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Patterns of Care and Treatment Outcomes Among Men Diagnosed with Prostate Cancer from Culturally and Linguistically Diverse Backgrounds: A Scoping Review.Current oncology reports · 2025Article
- Racial disparities in prostate cancer in the UK and the USA: similarities, differences and steps forwards.Nature reviews. Urology · 2025Review
- Advancing Prostate Cancer Diagnostics: A ConvNeXt Approach to Multi-Class Classification in Underrepresented Populations.Bioengineering (Basel, Switzerland) · 2025Article
- Incidence trends in prostate cancer among men in the United States from 2000 to 2020 by race and ethnicity, age and tumor stage.Frontiers in oncology · 2023Article
- Prognostic Factors for Overall Survival of Patients with Prostate Cancer in Kyadondo County, Uganda.Prostate cancer · 2020Article
- Predicting Gleason score using the initial serum total prostate-specific antigen in Black men with symptomatic prostate adenocarcinoma in Nigeria.Clinical interventions in aging · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies have reported higher rates of advanced Gleason score among black versus white men with prostate cancer in the United States. However, few studies have examined if elevated Gleason scores among black men vary by country of birth. We examined differences in prostate cancer disease severity among US black men born in the United States and in Jamaica, West Africa and other sub-Saharan Africa countries.
methodsOur study included 19 798 US-born, 267 Jamaican-born, and 246 West African-born black men diagnosed with prostate cancer during 2004-2009 in the 18 Surveillance Epidemiology and End Results population-based cancer registries. We evaluated the association of advanced Gleason score (7-10), as well as PSA levels and stage by country of origin adjusting for age, and county-level income.
resultsAmong men with known Gleason score, the percentage of advanced Gleason score (scores 7-10) was 61.11% in Jamaican-born, 60.99% in West African-born and 58.26% in US-born black men (P-value=0.49). In a multivariable analysis among black men, there were no differences in advanced Gleason score (scores 7-10 versus 2-6) by country of origin. Mean PSA level (range 12.8-13.1 ng ml(-1)) did not vary among black men (P-value=0.94) in unadjusted and adjusted results.
conclusionsSimilar Gleason score among US-born, African and Caribbean-born black men were observed. Future more detailed studies are needed to elucidate if these similarities are a result of similar early detection practices or shared risk factors.
Indexed as
Identifiers
23338555What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.